RxDoctor Payments Data

Andrew Defilippis, MD

Cardiovascular Disease · Nashville, TNNPI 1316969876

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Novo Nordisk at 59.3% of the total. Reporting peaked in 2024 at $4,021 and has fallen 90.2% since, to $393 in 2025.

$5,721in general payments, 2019–2025

Across 28 payments — averaging $204.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Abiomed$1K
  • Boston Scientific$412
  • Radiometer America, Inc$250
  • Regeneron Healthcare Solutions, Inc.$205
  • Inari Medical, Inc.$137
  • plus $222 from 3 others
$176,843in research payments, 2019–2025

Across 6 payments — averaging $29,474 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$119K
  • Janssen Research & Development, LLC$58K

What the payments were for

  • Consulting fees$3,35059%
  • Food & beverage$2,37141%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,721 in reported general payments places this provider in the 70th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$33,154
Medicare patients
481
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →